

# CONTENTS

---

Preface .....	vii
Contributors .....	xi
Value-Added eBook/PDA .....	xiv

## Part I: In Vitro Methods

1 High-Volume Screening .....	3
<i>Michel Pagé</i>	
2 High-Throughput Screening in Industry .....	23
<i>Michael D. Boisclair, David A. Egan, Kety Huberman, and Ralph Infantino</i>	
3 The NCI Human Tumor Cell Line (60-Cell) Screen: <i>Concept, Implementation, and Applications</i> .....	41
<i>Michael R. Boyd</i>	
4 Human Tumor Screening .....	63
<i>Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff</i>	

## Part II: In Vivo Methods

5 Murine L1210 and P388 Leukemias .....	79
<i>William R. Waud</i>	
6 In Vivo Methods for Screening and Preclinical Testing: <i>Use of Rodent Solid Tumors for Drug Discovery</i> .....	99
<i>Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh, Kathryn White, Juiwanna Knight, Lisa Demchik, Julie Jones, Lynne Jones, and Loretta Lisow</i>	
7 Human Tumor Xenograft Models in NCI Drug Development .....	125
<i>Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, and William R. Waud</i>	
8 NCI Specialized Procedures in Preclinical Drug Evaluations .....	153
<i>Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, and Sherman F. Stinson</i>	
9 Patient-Like Orthotopic Metastatic Models of Human Cancer .....	183
<i>Robert M. Hoffman</i>	
10 Preclinical Models for Combination Therapy .....	213
<i>Beverly A. Teicher</i>	
11 Models for Biomarkers and Minimal Residual Tumor .....	243
<i>Beverly A. Teicher</i>	

- 12 Spontaneously Occurring Tumors in Companion Animals As Models  
for Drug Development ..... 259  
**David M. Vail and Douglas H. Thamm**

### Part III: Nonclinical Testing to Support Human Trials

- 13 Nonclinical Testing: *From Theory to Practice* ..... 287  
**Denis Roy and Paul A. Andrews**
- 14 Nonclinical Testing for Oncology Drug Products ..... 313  
**Paul A. Andrews and Denis Roy**
- 15 Nonclinical Testing for Oncology Biologic Products ..... 325  
**Carolyn M. Laurençot, Denis Roy, and Paul A. Andrews**

### Part IV: Clinical Testing

- 16 Working With the National Cancer Institute ..... 339  
**Paul Thambi and Edward A. Sausville**
- 17 Phase I Trial Design and Methodology for Anticancer Drugs ..... 351  
**Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin**
- 18 Phase II Trials: *Conventional Design and Novel Strategies  
in the Era of Targeted Therapies* ..... 363  
**Keith T. Flaherty and Peter J. O'Dwyer**
- 19 Drug Development in Europe: *The Academic Perspective* ..... 381  
**Chris Twelves, Mike Bibby, Denis Lacombe, and Sally Burtles**
- 20 The Phase III Clinical Cancer Trial ..... 401  
**Ramzi N. Dagher and Richard Pazdur**
- 21 Assessing Tumor-Related Symptoms and Health-Related Quality of Life  
in Cancer Clinical Trials: *A Regulatory Perspective* ..... 411  
**Judy H. Chiao, Grant Williams, and Donna Griebel**
- 22 The Role of the Oncology Drug Advisory Committee  
in the FDA Review Process for Oncologic Products ..... 421  
**Leslie A. Vaccari**
- 23 FDA Role in Cancer Drug Development and Requirements  
for Approval ..... 429  
**Susan Flamm Honig**
- Index ..... 443



<http://www.springer.com/978-1-58829-228-5>

Anticancer Drug Development Guide  
Preclinical Screening, Clinical Trials, and Approval  
Teicher, B.A.; Andrews, P.A. (Eds.)  
2004, XIV, 451 p. 161 illus., Hardcover  
ISBN: 978-1-58829-228-5  
A product of Humana Press